Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: A composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy.

Oncotarget·2026
Same author

Triple Blockade of Oncogenic RAS Signaling Using KRAS and MEK Inhibitors in Combination with Irradiation in Pancreatic Cancer.

International journal of molecular sciences·2024
Same author

Neuropilin2 in Mesenchymal Stromal Cells as a Potential Novel Therapeutic Target in Myelofibrosis.

Cancers·2024
Same author

Treatment of acute myeloid leukaemia in older patients - scope of intensive therapy? - A retrospective analysis.

Hematology (Amsterdam, Netherlands)·2023
Same author

Development of Skin Rash Predicts Outcome of Anti-PD-1- and Anti-CTLA4-Based Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer or Squamous Cell Carcinoma of the Head and Neck: A Single-Center Analysis.

Oncology research and treatment·2021
Same author

β<sub>2</sub>-microglobulin triggers NLRP3 inflammasome activation in tumor-associated macrophages to promote multiple myeloma progression.

Immunity·2021

Related Experiment Video

Updated: Jun 17, 2026

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

Dextran-doxorubicin/chitosan nanoparticles for solid tumor therapy.

Savita Bisht1, Amarnath Maitra

  • 1Department of Chemistry, University of Delhi, Delhi, India.

Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology
|January 6, 2010
PubMed
Summary
This summary is machine-generated.

Targeted delivery of anticancer drugs using chitosan nanoparticles enhances tumor treatment. This approach improves drug concentration at the tumor site via the enhanced permeability and retention (EPR) effect, reducing side effects.

More Related Videos

Using In Vitro Live-cell Imaging to Explore Chemotherapeutics Delivered by Lipid-based Nanoparticles
10:26

Using In Vitro Live-cell Imaging to Explore Chemotherapeutics Delivered by Lipid-based Nanoparticles

Published on: November 1, 2017

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
09:56

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Published on: August 2, 2016

Related Experiment Videos

Last Updated: Jun 17, 2026

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

Using In Vitro Live-cell Imaging to Explore Chemotherapeutics Delivered by Lipid-based Nanoparticles
10:26

Using In Vitro Live-cell Imaging to Explore Chemotherapeutics Delivered by Lipid-based Nanoparticles

Published on: November 1, 2017

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
09:56

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Published on: August 2, 2016

Area of Science:

  • Nanomedicine
  • Oncology
  • Drug Delivery

Background:

  • Chemotherapy faces challenges in solid tumors due to poor drug delivery and pharmacokinetics.
  • Tumor pathophysiology, including poor perfusion and high interstitial pressure, hinders effective drug uptake.
  • Targeted delivery systems are crucial for improving cancer treatment efficacy and reducing side effects.

Purpose of the Study:

  • To review the progress in targeted delivery of nanoparticulated anticancer drugs for solid tumors.
  • To highlight the use of doxorubicin conjugated with dextran and encapsulated in chitosan nanoparticles.
  • To demonstrate the potential of reducing drug side effects through targeted delivery.

Main Methods:

  • Utilizing long-circulating hydrogel nanoparticles of controlled size (<100 nm).
  • Employing dextran-conjugated doxorubicin encapsulated in chitosan nanoparticles.
  • Leveraging the enhanced permeability and retention (EPR) effect for tumor accumulation.

Main Results:

  • Controlled particle size and long circulation of nanoparticles facilitate tumor accumulation via the EPR effect.
  • Significant regression of tumor volume observed, indicating therapeutic efficacy.
  • Minimized cardiotoxicity of doxorubicin through conjugation with dextran and encapsulation in chitosan nanoparticles.

Conclusions:

  • Targeted delivery of nanoparticulated anticancer drugs holds immense potential for improving cancer treatment.
  • Chitosan nanoparticles offer a promising platform for delivering chemotherapeutics like doxorubicin effectively.
  • This strategy can enhance therapeutic outcomes while mitigating severe side effects associated with conventional chemotherapy.